After completion of its mandatory tender offer in Fortis Healthcare and Fortis Malar Hospitals, Malaysian health care giant IHH Healthcare is aiming to add 2,000 beds in a bid to double down on value creation in India. IHH, which is Asia's largest multinational private healthcare provider, currently has over 5,000 beds across a combined network of 35 hospitals and 11 states.
At present, there is no provision under Drugs Rules, 1945 to address issues of wrong information to obtain regulatory approvals.
The Supreme Court refused to interfere with an order dismissing Jacqueline Fernandez's plea to quash an ECIR in a Rs 200 crore money laundering case involving Sukesh Chandrasekhar.
In August, the ED had raided the residential premises of former Ranbaxy CEO Malvinder Mohan Singh and his brother Shivinder Singh in connection with a money laundering case.
Ranbaxy's US factory, Ohm Laboratories, is learnt to have got a clean chit from the American regulator. This US facility was under surveillance of the Food and Drug Administration (FDA) since the end of 2012.
The company has admitted it fudged data so that it could launch its products in the United States. It has now paid $500 million as a penalty to settle the case.
Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.
Sun Pharma to retain these in most markets; US could be the exception, where the Ranbaxy name has taken a hit.
Ukraine is currently in the middle of a strategic offensive into Russia's Kursk region.
Almost a year after announcing a $4 billion deal, Sun Pharmaceutical Industries on Tuesday said merger of Ranbaxy with itself has been 'consummated.'
On January 31, the US Federal Trade Commission cleared the merger.
The proposed merger would likely harm future competition
The move comes in the wake of many facilities of Ranbaxy in India being barred by the US Food and Drugs Administration for supplying medicines to the US.
The move follows an FDA inspection of a Ranbaxy facility which identified significant violations of sound manufacturing practices.
India's largest drug maker Ranbaxy was at the receiving end of two patent infringement cases in Denmark and the USA on February 23
In a boost to Ranbaxy in its ongoing litigation over anti-cholesterol drug Lipitor (atorvastatin) against Pfizer, a Norway court today ruled that four of the US pharma giant's patents were either invalid or not infringed by the Indian company.
Sun-Ranbaxy are keen to complete the merger process.
FDA allows Teva to launch Nexium generic; Cipla, which supplies formulation, to gain
The court also restrained RHC Holdings from operating its bank accounts except for payment of salaries and statutory dues till March 23, the next date of hearing.
Ranbaxy Laboratories on Monday announced the launch of its drug for Benign Prostatic Hyperplasia in India.
Patient safety and quality our guidance now, says CEO and MD Arun Sawhney.
"We are responding to all queries from US FDA and will emerge as a stronger player in the world's biggest pharmaceutical market," Ranbaxy Chairman and Managing Director Malvinder Singh said. The US, which accounts for 20 per cent of Ranbaxy's $1.5-billion annual turnover, has an import restriction on 30 of its medicines by the US Food and Drugs Authority.
The generic drugs at issue were manufactured at Ranbaxy's facilities in Paonta Sahib and Dewas in India and included acne drug Sotret, epilepsy and nerve pain drug gabapentin and antibiotic ciprofloxacin.
.jpg)
According to sources, the company has identified smaller markets such as Peru, which do not contribute significantly to profits, where it might shut shop in the near term.
The United States district court of Maryland has given 60 days time to Ranbaxy to submit all documents sought by the Department of Justice through an information-seeking motion before the court on July 3.
FDA had cancelled Ranbaxy's approvals to launch generic Nexium, Valcyte
Continuing its expansion in Europe, Ranbaxy Laboratories Ltd on Tuesday said it has entered into the Italian pharmaceutical market with the launch of a wholly owned subsidiary, Ranbaxy Italia SPA, in Milan.\n\n
Close on the heels of the UK high court delivering a mixed verdict on the patent case of cholesterol lowering drug, atorvastastin between Ranbaxy and Pfizer, a Norwegian court has given another mixed ruling.\n\n
It is unlikely that independent directors on Ranbaxy Board had no exposure to corporate governance models.
Ranbaxy Ghuangzhou China is a joint venture formed in 1993 between the Ranbaxy group, Guangzhou Baiyunshan Pharmaceutical Company Ltd, China and Hong Kong New Chemic.
The company has been reported to be retrenching staff.
The US arm of Ranbaxy pleaded guilty to seven felonies relating to the manufacture and distribution of certain adulterated drugs
While Watson is a near comparable to Ranbaxy in terms of the generics business in the US, on margins and capital efficiency front, Ranbaxy is way ahead of Watson.
Ranbaxy has acceded to the request of Health Canada to quarantine drugs produced from its Paonta Sahib facility at Himachal Pradesh, North American country's newspapers reported, highlighting the trouble in store for the Japanese-controlled drug maker. Health Canada is a department of the government of Canada with responsibility for national public health.
US country head, key departmental heads leave; more likely to follow.
The Gurgaon-headquartered drug maker, set to be acquired by another leading domestic company, Sun Pharmaceutical Industries, reported a consolidated net loss of Rs 186 crore for the quarter ended June.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances